Ben Venue Laboratories, the Bedford, Ohio-based subsidiary of German drugmaker Boehringer Ingelheim, has hired Bank of America Merrill Lynch to explore a possible sale of its generic sterile injectable drugs business.
Ben Venue had struggled to keep the Ohio site open after a series of drug quality problems and had been operating under a consent decree with FDA until ultimately deciding in October to cease production and avoid additional investment.
No potential sale price or bidders have been mentioned yet.
